Compare Globus Medical Inc. Class A Common Stock (GMED) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Altria Group Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Altria Group Inc trades at $73.54 (market cap $119.49B). The key difference: Altria Group Inc is far larger — about 11.7× Globus Medical Inc. Class A Common Stock's market cap, and Altria Group Inc pays a 6.2% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Altria Group Inc for 155 Days on average.
| GMED | MO | |
|---|---|---|
Market Cap | $10.25B | $119.49B |
Volume | 1,108,124 | 6,945,035 |
Sector | Health | Consumer Staples |
52-Week High | $96.82 | $74.92 |
52-Week Low | $58.33 | $54.72 |
Typical Hold Time | 0 Days | 155 Days |
Enterprise Value | $9.76B | $141.70B |
Dividend Yield | — | 6.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Altria Group (MO) trades at $73.16, up 2.09% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company maintains strong profitability with 39% net income margin and generates robust operating cash flow of $9.3B. Recent earnings show alternating beats and misses, while analyst consensus remains positive with 61.5% buy ratings despite negative shareholder equity of -$2.24B.
MO offers a high dividend yield but faces structural challenges including declining cigarette volumes and regulatory uncertainty. The stock trades below analyst consensus target of $69.71, suggesting limited upside. Key risks include negative equity, margin compression, and dependence on declining tobacco products despite smoke-free initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
